Font ResizerChange Colors
Ελληνικά
search icon

Biomedical Projects

PMN - Hellenic Network of Precision Medicine on Cancer

The Hellenic National Network for Precision Medicine (Personalized Medicine) is a pioneering action at European level that makes Greece a participant in shaping the future of Medicine. The aim of this Network is, through Research, the identification of the predisposition to the manifestation of a particular disease and its relation to the genetic inheritance, the environment and the way of life of each individual patient. On the other hand, in cases where the disease has already occurred, the personalized medical and pharmaceutical treatment, based on research findings, can increase the treatment effectiveness while reducing significantly the cost of care. The implementation of the Hellenic Network for Precision Medicine flagship activity requires the creation of specialized units of gene and molecular analysis (next-generation DNA sequencing) as well as the existence of accredited biobanks (clinical patient collection Banks). It is worth noting that all data will be collected and processed on computing platform that will be configured within the Network creating, thus, a dynamic database valuable for future research exploitation. The ultimate aim of the Hellenic Network for Precision Medicine, in cooperation with the Ministry of Health, is to make accessible to all citizens through the Public Health System the clinical applications of Personalized Medicine.


Funding Body: The Hellenic Network of Precision Medicine on Cancer is funded under the framework of the Hellenic Republic – Siemens Settlement Agreement
Project duration: 08/2018 - 12/2021
Official project's website
https://oncopmnet.gr/
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272




GR-CERTH-2019-PLATFORMS

The aim of this project is to raise the quality and sustainability of research software by producing, adopting, promoting and measuring information standards and best practices applied to software development life cycle.


Funding Body: ELIXIR Hub
Project duration: 12/2019 - 12/2021
Official project's website
: https://elixir-europe.org/platforms
Contact: Fotis Psomopoulos
E-mail: fpsom@certh.gr
Tel: +30 2310498478



Biobanking and Biomolecular Resources Research Infrastructure

The BBMRI-GR will be created to be the first and only to date interdisciplinary National Research Infrastructure (NRS) designed to provide open access for research purposes to human biological samples and the clinical and other data that accompany them to users from the public. and the private sector.


Funding Body: Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK)
Project duration: 02/2019 - 02/2022
Official project's website
: http://www.bbmri.gr/
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272



cervHPVix - An Integrated Biomolecular Approach Towards Innovative Triage of High-Risk HPV Positive Women For The Prevention Of Cervical Cancer

Study of an Integrated Biomolecular Approach Towards Innovative Triage of High-Risk HPV Positive Women For The Prevention Of Cervical Cancer


Funding Body: Roche Hellas S.A.
Project duration: 12/2019 - 12/2021
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272


Γαληνός - Εταιρεία - Roche Hellas Α.Ε.

Heads Lab Services

During the study INAB-CERTH will perform the following assessments:



  • FLOW Cytometry FACS

  • HLA Typing

  • Next Generation Sequencing analysis of T-Cell repertoire


Funding Body: Health Data Specialist IRELAND LIMITED
Project duration: 02/2018 -01/2020
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474

Heads Lab Services

During the study INAB-CERTH will perform the following assessments:



  • FLOW Cytometry FACS

  • HLA Typing

  • Next Generation Sequencing analysis of T-Cell repertoire


Funding Body: Health Data Specialist IRELAND LIMITED
Project duration: 06/2017 - 06/2023
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272

TF-TP63-CLL

Microenvironment and transcriptional regulation in chronic lymphocytic leukemia: a focus on the transcription factor TAp63 and its role in the anti-apoptotic phenotype of leukemic cells


Funding Body: Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK)
Project duration: 08/2018 - 12/2020
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272

COVID-19 and CLL

COVID-19 and CLL: Understanding the pattern of coronavirus 2 (SARS-CoV-2) and Coronavirus disease 2019 (COVID-19) in patients with chronic lymphocytic leukemia (CLL)


Funding Body: Ospedale San Raffaele S.R.L.
Project duration: 06/2021 - 04/2022
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272

ATXN1Q82-MED15 “Blocking the aggregation promoting ATXN1Q82-MED15 protein-protein interaction"

Spinocerebellar ataxia type-1 (SCA1) is an autosomal dominant and lethal neurodegenerative disorder characterized by progressive movement disorders. It belongs to the group of polyglutamine (polyQ) diseases. It is caused by trinucleotide (CAG) expansions in the coding region of ataxin-1 (ATXN1) gene resulting in polyQ chains in the relevant protein. The mutant protein misfolds into toxic oligomers and forms intranuclear aggregates that cause neurodegeneration in the cerebellum. We aim to identify the exact PPI site between ATXN1 and MED15 and block it with chemical compounds having a similar structure. These compounds may also suppress polyQ protein aggregation and reduce cytotoxicity. To minimize the experimental workload, we are going to use a combination of computational and experimental techniques. First, we aim to predict the ATXN1-MED15 PPI site using a protein-protein docking algorithm. This prediction will be validated in a quantitative cell-based PPI assay. Then, we are going to perform a virtual screening and select chemical compounds that have similar structure to the ATXN1-MED15 PPI site. These compounds will be tested whether they block ATXN1-MED15 PPI in cell-based assays. Finally, hit compounds will be tested whether they suppress MED15-mediated ATXN1Q82 protein aggregation in a novel stem cell model using automated high-content screening. We expect that compounds blocking ATXN1-MED15 PPI would also suppress polyQ protein aggregation in primary human cells. Such compounds would be candidates for the development of novel anti-aggregating drugs in polyQ diseases.


Funding Body: Hellenic Foundation for Researh and Innovation
Project duration: 07/2018 - 01/2022
Official project's website
: https://vcl.iti.gr/project/atxn1-med15-ppi/
Contact:  Spyros Petrakis
E-mail: spetrak@certh.gr
Tel: +30 2311257524


CHRODIS+ - Implementing good practices for chronic diseases

Europe is paying a heavy price for chronic diseases (CD): it has been estimated that CD cost EU economies 115 billion or 0.8% of GDP annually; and this figure does not include the additional loss in terms of lower employment rates and productivity of people living with chronic health problems. However, the aspiration is a health-promoting Europe, free of preventable CD, premature death and avoidable disability could be possible. Initiatives on CD should build on four cornerstones: health promotion and primary prevention as a way to reduce the burden of CD; patient empowerment; tackling functional decline and quality of life as the main consequences of CD, and making health systems sustainable and responsive to the aging of our populations associated with the epidemiological transition (an increase in incidence of CD and extended life expectancy) whose consequence is an increasing prevalence of CD. In this Joint Action, CHRODIS-PLUS, our goal is to support Member States through cross-national initiatives identified in JA-CHRODIS to reduce the burden of CD, while assuring health systems sustainability and responsiveness. CHRODIS-PLUS aims to promote the implementation of policies and practices with demonstrated success in each of the four cornerstones mentioned, in closely monitored implementation experiences that can be validated before scaling them up. For this, a total of 42 beneficiaries representing 20 European countries will collaborate to implement pilots and generate practical lessons that could contribute to the uptake and use of CHRODIS-PLUS results. Practices to be implemented will be based on the collection of policies, strategies and interventions that started in JA-CHRODIS and in its outputs such as the Integrated Multimorbidity Care Model or the Recommendations for Diabetes Quality criteria or national plans. During the 36-month life CHRODIS-PLUS will disseminate its activities and monitor and evaluate them to verify the progress and impact of the action. CHRODIS-PLUS will look for synergies with international/ regional/local policy initiatives in CD. CHRODIS-PLUS will count on the Governing Board of representatives from European Ministries of Health, key to CHRODIS-PLUS development and sustainability, an Executive Board and a General Assembly where all associated partners will gather. A proposal for the EU added value of cross-country collaboration in the field of CD and the sustainability of the results from JA-CHRODIS and CHRODIS-PLUS beyond 2020, when this project ends, will be approved.


Funding Body: EC - ΗORIZON 2020
Project duration: 09/2017 - 11/2020
Official project's website
: http://chrodis.eu/
Contact:  Pantelis Natsiavas
E-mail: pnatsiavas@certh.gr
Tel: +30 2311257608


CLL-KUWAIT

Statistical analysis for a cohort of patients with chronic lymphocytic leukemia.


Funding Body: Kuwait Cancer Control Hospital 
Project duration: 11/2020 - 02/2022
Contact:  Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


 

CLLon  - Immunogenetic and functional analysis of the B-cell receptor in Monoclonal B-cell Lymphocytosis (MBL) and Chronic Lymphocytic Leukemia (CLL): implications for disease ontogeny

CLLon aims at dissecting the processes related to the B-cell receptor immunoglobulin (BcR IG) that occur throughout the natural history of CLL and contribute to disease ontogeny and evolution through in-depth immunogenetic and functional studies of the clonotypic BcR IG.
To reach solid conclusions, the study group will comprise individuals with MBL of both subtypes: (i) low-count MBL (LC-MBL) and (ii) high-count MBL (HC-MBL), as well as patients with CLL with distinct clinical courses, ranging from ultra-stable (asymptomatic for at least 10 years) to rapidly progressive. A multiparametric characterization of the BcR properties in MBL and CLL will be performed at different levels: (i) IG heavy and light chain sequence composition, (ii) BcR reactivity profile and (iii) (classical and autonomous) BcR signaling capacity.


Funding Body: Hellenic Foundation for Researh and Innovation
Project duration: 07/2018 - 01/2022
Official project's website
http://www.cllon-hfri.gr/
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272



 

COSMIC - COmbatting disorders of adaptive immunity with Systems MedICine

COSMIC develops and integrate experimental and computational approaches and establish a unique crossfertilization between oncology and auto-immunity. In addition to transferable skills, the training program focuses on establishing a double expertise in laboratory and computational to address clinical questions. It involves a wide-range of stakeholders: (pre)clinical departments, companies, patient groups, students, and the general public. COSMIC will establish a link with the leading European EASyM and ISBE initiatives, and aims to harmonize systems medicine training throughout Europe by connecting to other EU (Marie Curie systems medicine) training initiatives. Impact: COSMIC (i) significantly improves ESR career perspectives (ii) leads to new public-private collaborations increasing competitiveness for companies; (iii) contributes to future oncology and immunology medical care; (iv) contributes to the EU systems medicine best practices.


Funding Body: EC - ΗORIZON 2020, Marie Skłodowska-Curie Innovative Training Networks (ITN/ETN)
Project duration: 01/2018 - 12/2021
Official project's website
https://www.cosmic-h2020.eu/
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272


COSMIC Logo

GenOptics - Large Scale bio-data Visual analytics platform

GenOptics is a 30-month national project (2020-2023) that will implement a new platform for integrating, analyzing and visualizing multi-omics and other clinico-biological data, by extending the functionality of established bioinformatic analysis tools through an interactive visual dashboard. Visual analytics, namely the simultaneous use of computational data analysis tools with interactive visualizations, is a powerful way of combining algorithms with an intuitive, user-friendly interactive environment in order to extract knowledge from large scale bio-data. Although visual analytics could contribute to significantly reducing the gap between available data and discovery of new knowledge through targeted studies, there is no widely used platform that provides this functionality to the scientific community. GenOptics will allow visual analytics of multi-omics data through a modular system that will integrate multiple interoperable analysis tools into a software platform, leveraging established international technologies and software suites such as Docker and R/Bioconductor.


Funding Body: Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK), EDK
Project duration: 06/2020 - 12/2022
Official project's website
https://genoptics.github.io/
Contact: Fotis Psomopoulos
E-mail: fpsom@certh.gr
Tel: +30 2310498478


GR Inherited Network - Precision Medicine In Cardiology: Towards A Strategy For The Prevention Of Sudden Cardiac Death In The Young

The Greek National Network of Precision Medicine in Cardiology and the Prevention of Sudden Death in the Young aims at the core of sudden death in the young using the latest developments in genetics, management, and treatment of inherited cardiovascular diseases.


Funding Body:  General Secretariat for Reaserch and Innovation
Project duration: 07/2019 - 06/2022
Official project's website
https://icardiacnet.gr/
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


2-1500×718-1

NEoteRIC - NEuromorphic Reconfigurable Integrated photonic Circuits as artificial image processor

NEoteRIC’s primary objective is the generation of holistic photonic machine learning paradigms that will address demanding imaging applications in an unconventional approach providing paramount frame rate increase, classification performance enhancement and orders of magnitude lower power consumption compared to the state-of-the-art machine learning approaches. NEoteRIC’s implementation stratagem incorporates multiple innovations spanning from the photonic “transistor” level and extending up to the system architectural level, thus paving new, unconventional routes to neuromorphic performance enhancement. The technological cornerstone of NEoteRIC relies on the development and upscaling of a high-speed reconfigurable photonic FPGA-like circuit that will incorporate highly-dense and fully reconfigurable key silicon photonic components (ring resonators, MZIs, etc.). High-speed reconfigurability will unlock the ability to restructure the photonic components and rewire inter-component connections. Through NEoteRIC the integrated photonic FPGAs will be strengthened by the incorporation of novel marginal-power consuming non-volatile high-speed phase shifters that will push the boundaries of energy consumption. NEoteRIC’s “unconventional” chips will be utilized as a proliferating neuromorphic computational platform that will merge the merits of photonic and electronic technology and will allow the alloptical implementation of powerful non-von Neumann architectures such as Reservoir Computing, Recurrent Neural Networks, Deep Neural Networks and Convolutional Neural Networks simultaneously by the same photonic chip. The in-project excellence will be tested through demanding high impact application such as high frame-rate image analysis and in particular single-pixel time-stretch modalities thus pushing the boundaries of state-of-the-art; exhibiting simultaneous high spatial resolution and Gframe/sec processing rate.


Funding Body:  EC - ΗORIZON 2020
Project duration: 01/2020 - 12/2023
Official project's website
https://neoterich2020.eu
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272


Official start of the NEoteRIC H2020 EU funded Action Press Release -  Computer and Communication Systems Laboratory

HIV Patients Holistic Assessment

The advent of new treatments and regimens over the last 30 years has been fundamental for changing the natural history of HIV infection, turning it from a deadly and life-threatening disease into a chronic disease that can be treated with appropriate medication. As a result, people living with HIV infection (HIV-positive people) begin to experience similar problems with patients with a chronic non-contagious disease, with the added burden of developing comorbidities associated with aging, antiretroviral therapy, or and the combination of these. It is therefore obvious that complex and comprehensive approaches are needed for the individualized and specialized care of HIV-positive people, in order to enhance their care and quality of life. In the context of utilization of the infrastructure and the specialized staff of CERTH|INAB, GILEAD has commissioned the elaboration of data recording concerning the assessment of the needs of care as perceived and expressed by both HIV-positive people in care in the infection units in Greece as well as physicians dealing with HIV infection, and in the assessment of epidemiological and clinical laboratory parameters of patients in combination with scientific tools (such as questionnaires) to assess the quality of life-related to health, attitudes, and perceptions about the disease and its treatment as well as adherence to chronic treatment of HIV infection.


Funding Body:  Gilead Sciences Hellas
Project duration: 12/2018 - 06/2021
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272


 


Gilead Logo

IbruTcel - Immune effects of Ibrutinib on the CLL microenvironment: pre- and post-treatment T-cell profiling

The proposed study will further investigate the impact of ibrutinib on CLL T cells by longitudinal, pre- and post-treatment profiling of the TR repertoire combining NGS, phenotyping and functional assays. To this end, we will seek for possible associations between TR repertoire dynamics and clinical responses, aiming to reveal immune signatures either pre- or post-ibrutinib treatment that may serve as predictors of response, thereby assisting in refining treatment strategies.


Funding Body:  Janssen Research & Development LLC
Project duration: 05/2020-11/2021
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


Janssen Pharmaceuticals - Wikipedia

IMPACT - Advanced Industrial Materials from Olivine for APplicAtions in Casting and
STeel Industry

The main concept of the IMPACT proposal is the development of improved materials based on the industrial mineral olivine having to main goals: i) the increase in the refractoriness of refractory masses for applications in the steel industry and the ii) substitution of silicon oxide in the casting sand in foundries with a more environmentally friendly raw material.


Funding Body: Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK)
Project duration: 02/2020 - 04/2022
Official project's website
http://www.impact.certh.gr/
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


 

LymphBio - Lymphoma Biospeciments

Clinically annotated, molecular typed (baseline prognostic molecular markers) chronic lymphocytic leukemia (CLL) freshly frozen viable cell suspensions n=8 per month, and lymphoma biopsy tissue viable frozen cell suspensions for ongoing collaborative projects


Funding Body: King's College London - Research Management & Innovation Directorate
Project duration: 07/2020-10/2021
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


King's Research | Research & Innovation | King's College London

MyPal - Fostering Palliative Care of Adults and Children with Cancer through Advanced Patient Reported Outcome Systems

MyPal aims to foster early palliative care for cancer patients by leveraging patient-reported outcome (PRO) systems through their adaptation to the personal needs of the cancer patient and his/her caregiver(s). Through this intervention, MyPal aspires to empower cancer patients (and their family members) in capturing more accurately their conditions, communicate them in a seamless and effective way to their healthcare providers and, ultimately, foster the time for action through the rapid identification of important deviations in the patient’s state and QoL. Providing this information in a timely and comprehensive manner throughout the disease course will reinforce the potential for applying a patient-centred and integrated palliative care approach for cancer with the participation of all relevant healthcare providers (i.e. oncologists, specialized physicians, psychologists, nurses), which is necessary to cope with the disease. In order to accomplish its mission, MyPal will exploit technological advances in digital health to support patients, family members and healthcare providers in gaining value through this systematic and comprehensive PRO-based intervention. Overall, the foreseen advancement through MyPal reflects a paradigm shift from passive patient reporting based on conventional PRO approaches to active patient engagement and a closed-loop approach (bridging the gap between patient reporting and effective actions by healthcare providers to meet the varying patient needs) for coping with palliative care challenges in cancer. MyPal will demonstrate and validate the proposed intervention in two clinical studies, an RCT for adults with hematologic cancers and an observational study for children suffering from solid tumors and hematologic malignancies, hence targeting different age groups and cancer types. The clinical studies will be conducted in diverse healthcare settings in 6 clinical sites in 5 European countries.


Funding Body: EC - ΗORIZON 2020
Project duration: 01/2019-12/2022
Official project's website
https://mypal-project.eu
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


 

MIMS - Metagenomic and Immunogenetic

The projects main goal is the metagenomic and immunogenetic analysis in Multiple Sclerosis


Funding Body: Hellenic Foundation for Research and Innovation
Project duration: 11/2020 - 11/2023
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


NeoCLL - Neoantigen and tumor-specific T cell discovery in chronilymphocytic leukemia

Recent next-generation sequencing (NGS) studies by our group documented the clonal architecture of the T cell repertoire in chronic lymphocytic leukemia (CLL), with T cell clones which persist and expand over time in treatment-naive CLL, appear disease-specific and may be shared among different patients, especially those belonging to stereotyped subsets. This indicates selection by restricted antigens that could actually be acting in a CLL subset-specific context. Furthermore, we have shown that B cell receptor (BcR) signaling inhibitors retain T cell clones that may have developed in response to tumor antigens. Ιmportantly, these clones expand and may become activated, possibly contributing in the clinical response, at least in certain cases. On these grounds, NeoCLL was launched with the aim to formally identify and fully characterize both immunogenic neoepitopes and the CD8 T cells that recognize them. We will take advantage of a novel, high-throughput method for detecting antigen-specific T cells using DNA-barcoded peptide-MHC-I multimers. Our study will focus on neoepitopes within the clonotypic BcR IG that may be conserved amongst CLL patients. The ultimate goal is to explore the possibility for a stratified treatment by means of engineered T cells or by peptide vaccines targeting such conserved epitopes.


Funding Body: European Hematology Association (EHA) 
Project duration: 03/2019 - 12/2021
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


EHA - European Hematology Association - Congrex Switzerland

HARMONY - Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in HematologY

Blood cancers, or haematologic cancers (e.g. leukaemia, lymphoma and myeloma), affect the production and function of blood cells and account for about one third of cancer cases in children and about one third of cancer deaths. As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and decision-makers alike. The HARMONY project aims to use ‘big data’ to deliver information that will help to improve the care of patients with these diseases. Specifically, the project will gather together, integrate and analyse anonymous patient data from a number of high quality sources. This will help the team to define clinical endpoints and outcomes for these diseases that are recognised by all key stakeholders. Meanwhile the project’s data sharing platform will facilitate and improve decision making for policy makers and clinicians alike to help them to give the right treatment to the right patient at the right time. More broadly, the project will result in a pan-European network of stakeholders with expertise in this disease area. The project is part of IMI’s Big Data for Better Outcomes programme, which aims to facilitate the use of diverse data sources to deliver results that reflect health outcomes of treatments that are meaningful for patients, clinicians, regulators, researchers, healthcare decision-makers, and others. INAB-CERTH is active within HARMONY both as an associated member but also thanks to its participation in ERIC, the European Research Initiative on CLL, full partner of this project.


Funding Body:  HARMONY Alliance /  Innovative Medicines Initiative (IMI)
Project duration: 01/2021 - 12/2021
Official project's website
: https://www.harmony-alliance.eu/
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr 
Tel: +30 2310498272


Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology

NEURO - Training program in experimental and clinical Neuroimmunology aimed at investigating autoimmune neurological diseases 

Educational program that focuses on experimental and clinical Neuroimmunology and aims to investigate autoimmune neurological diseases


Funding Body: GENESIS Pharma
Project duration: 10/2019 - 03/2021
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


genesis logo

nPETS - Nanoparticle Emissions from the Transport Sector: Health and Policy Impacts

NPETS aims to monitor and sample with state-of-the-art particle instruments the sub 100 nm transport generated emissions from shipping, road, rail, and aviation both in field and controlled laboratory environments. Both aged and fresh aerosols will be considered, including primary and secondary volatile and non-volatile particles. Characterizing the emissions will be done from shipping, road, rail, and aviation by linking their sizes, chemical compositions, and morphologies to its specific emission sources such as engines, brakes, clutches, and tyres to increase the understanding of the mechanisms behind adverse risks posed by different types and sources of the identified sub 100 nm particles. The effects of nanoparticles from various transport modes and fuels, as well as specific emission sources, will be compared with a focus on markers of relevance for carcinogenesis and inflammation. Living cells will be exposed to collected and real-world primary and aged aerosols as well as primary and aged aerosols generated in the laboratory. Furthermore, it also aims to evaluate the possible future impact of new policies in this area on public health and linking the impacts with specific emission sources. This should lead to an understanding and quantification of the risks posed by different types and sources.


Funding Body: EC - ΗORIZON 2020
Project duration: 06/2021 - 05/2024
Official project's website
https://www.npets-project.eu/
Contact: Spyros Petrakis 
E-mail: spetrak@certh.gr
Tel: +30 2311257524


nPETS

PrescIT - Smart, Personalized and Interoperable Electronic Prescription Platform

The object of the project is the implementation, evaluation and dissemination of a Clinical Decision Support System (CDSS) platform for more efficient, safer, standardized and economical electronic prescribing, initially nationally and in the future internationally. The project helps increase the quality of health services, productivity and security. More specifically, the objectives of the project are:



  1. Accelerate the process of rational determination of medication, and increase productivity, through the use of suggestions and recommendations based on the history of active comorbidities.

  2. The reduction of errors, and consequently the safer administration of drugs, systematizing the control of indications, contraindications and co-administration interactions.

  3. The reuse, standardization and future utilization of services, through the interoperability provided by interconnected data, semantic web and conceptual structures (ontologies, rules).

  4. The enrichment of the information available, e.g. through intelligent and automated processing of the literature at the level of semantic meaning, extracting additional knowledge

  5. The evaluation of the platform by the users, in terms of the friendliness and intuition of the user interfaces, but also its performance and suitability through pilot tests in three different clinical environments and three usage scenarios

  6. The dissemination and commercialization of the results through integration in national portals and in the already existing service galinos.gr


Funding Body: Co‐financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE - INNOVATE
Project duration: 07/2021 - 01/2023
Official project's website
https://www.prescit.com/
Contact: Pantelis Natsiavas
E-mail: pnatsiavas@certh.gr
Tel: +30 2311257608


PureCell - Towards Precision Medicine: Advanced cellular analytics in biomedical research

MAin goal is the establishment of a National Open Infrastructure for Advanced Cellular Analytics in biomedical research that will be relevant to not only INAB-CERTH scientists and collaborators but the academic sector at large that will have increased opportunities for cutting-edge research.


Funding Body: Hellenic Foundation for Researh and Innovation
Project duration: 03/2021 - 03/2024
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272


PVClinical - Active Pharmacovigilance in Clinical Environments

PVClinical proposes the design and implementation of a novel Information Technology (IT) platform, aiming to facilitate the identification, investigation and management of candidate Adverse Drug Reaction (ADR) signals in the clinical context. An ADR “signal” is defined as a possible causal relationship between a drug and an adverse reaction or medical condition. The PVClinical platform will exploit a number of different information sources that have been relatively neglected in traditional pharmacovigilance practices. The proposed design focuses on the unified and holistic integration of these heterogeneous data sources (international scientific literature, social media, Electronic Health Records and ADR Spontaneous Report Systems). The implementation emphasizes on the capabilities of integrating the proposed platform in existing clinical information systems via an unobtrusive manner, therefore reinforcing drug safety in everyday clinical practice.


Funding Body: Co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE - INNOVATE
Project duration: 09/2018 - 09/2022
Official project's website
: https://pvclinical-project.eu/
Contact: Pantelis Natsiavas
E-mail: pnatsiavas@certh.gr
Tel: +30 2311257608



 

Take-A-Breath -  Smart Platform for Self-Management and Support for Patients with Chronic Respiratory Diseases

The project “Take-A-Breath” focuses on the design, research and development of an innovative system of personalized monitoring services for respiratory diseases through the combination of clinical research and new bio-indicators with innovative ICT technologies, such as gamification techniques. Specifically, it enables the guidance of patients to manage their own health, by providing user-friendly tools and applications to increase awareness of the clinical situation and the effectiveness of their health care and compliance to treatment. In particular, the work focuses on clinical research into new biomarkers associated with respiratory diseases, addressing a wide range of parameters of behavioral, environmental and psycho-emotional state of the person. In addition, it adopts and develops an ambitious and innovative approach to monitor the use of inhaled respiratory drugs, combined with techniques to learn how to use it properly, through a holistic approach to self-management, medical assistance and self-improvement. On this basis, a bio-surveillance network with capacity to adapt to any inhaler will be developed using non-intrusive sensors, along with an ICT system which is capable of: (a) to collect a multitude of data relating to the above during everyday activities of the user; (b) to educate patients on the correct use of inhalation devices, using innovative signal processing and computer vision techniques, with gamification techniques and mechanisms, as well as using virtual characters and interactive narrations, and (c) to provide guidance to the patient when it is required in conjunction with a decision support system and appropriate interventions (receiving medical assistance, self-management of asthma attacks etc.).


Funding Body: Co-financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE - INNOVATE
Project duration: 07/2018 - 07/2022
Official project's website
https://www.take-a-breath.gr/
Contact: Pantelis Natsiavas
E-mail: pnatsiavas@certh.gr
Tel: +30 2311257608



 

TRANSCAN NOVEL -  Employing NGS technology for improved, non-invasive early detection, staging and prediction of progression in lymphoma patients

Aligning national/regional translational cancer research programmes and activities, TRANSCAN-2 The project is expected to achieve validated and implemented procedural and analytical pipelines for NGS profiling of B-NHL/CLL-specific biomarkers in liquid biopsies. We will also define validated and implemented bioinformatics workflows and tools for widespread use in a diagnostic setting. The successful completion of the NOVEL proposal will allow to achieve accurate outcome prediction and improved survival through risk stratification of individuals carrying pre-lymphomatous or indolent conditions for evolution to overt lymphoma and refined molecular diagnosis/staging in the aggressive forms. Potentially, the procedural and analytical pipelines could be utilized also for the management of other neoplastic conditions.


Funding Body: European Cooperation - Subsidy for Greek Institutions that participated successfully in the European Networks Joint Calls for Proposals - Era-Nets
Project duration: 01/2019 - 01/2022
Official project's website
https://www.transcanfp7.eu/index.php/abstract/novel.html
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


 TRANSCAN-3

TRANSCAN Quant-ALL - Automated, absolute quantification of MRD in ALL patients by droplet microfluidics, single DNA copy barcoding and IG/TR amplicon NGS 

The assessment of minimal residual disease (MRD) during first-line therapy is regarded as most important prognostic factor in adult and childhood acute lymphoblastic leukemia (ALL). However, current methods used for MRD assessment have major drawbacks.  The goal and hypothesis of Quant-ALL is to eliminate these disadvantages by a combination of innovative high throughput molecular tools. Aims and methods: (1) Establishment of an amplicon based IG/TR NGS approach using single DNA copy barcoding and droplet microfluidics for IG/TR based MRD quantification in ALL. (2) Optimization of existing bioinformatics tools used for IG/TR NGS to quantify index IG/TR sequences. (3) Transfer of this technology to a pre-existing centrifugal microfluidic platform for full automation and standardization. (4) Validation of technology for childhood and adult ALL using biobanked follow-up samples that are MRD quantified with standard technologies. Expected results are the full automation of a high throughput technology for MRD quantification in ALL. This technology will be standardized and validated to allow a wide distribution to ALL MRD reference laboratories and fundamentally improve MRD quantification in childhood and adult.


Funding Body: European Cooperation - Subsidy for Greek Institutions that participated successfully in the European Networks Joint Calls for Proposals - Era-Nets
Project duration: 02/2020 - 02/2023
Official project's website
https://www.transcanfp7.eu/index.php/abstract/quant-all.html
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


 TRANSCAN-3

TRANSCELL - Innovative approaches for T cell immunotherapy post allogeneic

The project aims to develop and administer, for the first time in Greece, advanced T-cell therapies by using cost-effective and “user-friendly” protocols for the treatment of opportunistic infections and GvHD, representing the major complications post allo-HSCT. This endeavor will be accomplished through a productive and complementary partnership between 3 research organizations and 2 enterprises. Main goal is to release for use, after preclinical development, GMP validation, in-depth immunophenotypic, molecular and functional characterization, and after obtaining approvals from the regulatory agencies, two innovative T-cell products:



  1. pentavalent-specific T cells (penta-STs) for the treatment of life-threatening infections from cytomegalovirus-CMV, Epstein Barr virus-EBV, adenovirus-ADV, polyomavirus type I-BK and the fungus Aspergillus, and

  2. inducible, through pharmacological hypomethylation, T regulatory cells expressing the HLA-G+ (iG-Tregs) for the treatment of severe GvHD.


Funding Body: Co‐financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE
Project duration: 07/2020 - 01/2023
Official project's website
https://transcell.gr/
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


 Transcell

Transplant MS - Stem Cell Transplantation in a Multiple Sclerosis Animal Model for Effective Cell Therapy

The object of the project is stem cell transplantation in experimental autoimmune encephalomyelitis which is the most representative and reliable animal model of multiple sclerosis. The project aims to discover more effective treatments than current existing ones, for neurodegenerative autoimmune disease.


Funding Body: Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK)
Project duration: 05/2020 -  02/2022
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474

VENETO - Immunogenetic analysis of Venetoclax treated patients

The purpose of the Veneto project is to investigate the immune effects of Venetoclax on the T-cells in CLL by performing pre- and post-treatment high-throughput profiling on the T-cell repertoire. Samples for this study were collected from patients receiving Venetoclax as monotherapy who were treated in the Hematology Department and Hematopoietic Cell Transplantation Unit, G. Papanikolaou Hospital, Thessaloniki, Greece, in accordance with the provisions of the GDPR. Samples were sent to the Institution fully anonymized.


Funding Body: AbbVie Inc.
Project duration: 10/2019-10/2022
Contact: Anastasia Chatzidimitriou
E-mail: achatzidimitriou@certh.gr
Tel: +30 2310498474


 PharmaBoardroom - AbbVie China

ODYSSEAS - Intelligent και Automated systems for enabling the design, simulation and development of
integrated processes and products

The objective of the Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products - "ODYSSEAS” project is the implementation of a contemporary digital infrastructure in order to provide an intelligent and automated production for the partners of the CERTH. This objective will be achieved by utilizing effectively the existing technical know-how and the available infrastructures, while introducing pioneering technological methods for product digitalization, production and management.


Funding Body: Operational Programme Competitiveness, Entrepreneurship and Innovation 2014-2020 (EPAnEK)
Project duration: 10/2017 - 10/2021
Contact: Kostas Stamatopoulos
E-mail: kostas.stamatopoulos@certh.gr
Tel: +30 2310498272